Cardiac sarcoidosis and giant cell myocarditis after COVID-19 infection

Case Reports

doi: 10.1002/ehf2.14088.

Online ahead of print.


Item in Clipboard

Case Reports

Entela Bollano et al.

ESC Heart Fail.



Patients infected with SARS-CoV-2 have varying manifestations of cardiac involvement. We report four patients presenting with symptomatic cardiac sarcoidosis (CS) or giant cell myocarditis (GCM) 1-8 months after mild COVID-19. All patients received immunosuppressive therapy and improved gradually within the following months. The possible temporal association between the CS/GCM and COVID-19 infection might suggest that COVID-19 could be a trigger for granulomatous myocarditis.


COVID-19; Cardiac sarcoidosis; Giant cell myocarditis; Heart failure.


    1. Escher F, Pietsch H, Aleshcheva G, Bock T, Baumeier C, Elsaesser A, Wenzel P, Hamm C, Westenfeld R, Schultheiss M, Gross U, Morawietz L, Schultheiss HP. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Fail. 2020; 7: 2440-2447.

    1. Basso C, Leone O, Rizzo S, de Gaspari M, van der Wal AC, Aubry MC, Bois MC, Lin PT, Maleszewski JJ, Stone JR. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J. 2020; 41: 3827-3835.

    1. Kawakami R, Sakamoto A, Kawai K, Gianatti A, Pellegrini D, Nasr A, Kutys B, Guo L, Cornelissen A, Mori M, Sato Y, Pescetelli I, Brivio M, Romero M, Guagliumi G, Virmani R, Finn AV. Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC review topic of the week. J Am Coll Cardiol. 2021; 77: 314-325.

    1. Satterfield BA, Bhatt DL, Gersh BJ. Cardiac involvement in the long-term implications of COVID-19. Nat Rev Cardiol. 2021; 19: 332-341.

    1. Carubbi F, Alunno A, Leone S, di Gregorio N, Mancini B, Viscido A, del Pinto R, Cicogna S, Grassi D, Ferri C. Pericarditis after SARS-CoV-2 infection: another pebble in the mosaic of long COVID? Viruses. 2021; 13.

Source link

Back to top button